Marshall Horwitz

Has grant

Professor

Washington University School of Medicine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Marshall Horwitz is a Professor at the University of Washington School of Medicine in the United States. His research focuses on the role of neutrophil elastase and its related genetic mutations, particularly in relation to granulocytic differentiation. Recent publications include discussions on the implications of ELANE mutations and their effect on protein processing within cells.

Recent Grants

Grant: Close

Pathogenesis of ELANE-Associated Neutropenia

Open Date: 2016-01-15

Close Date: 2019-11-30

Grant: Close

Translational Control in Bone Marrow Failure

Open Date: 2013-05-01

Close Date: 2016-04-30

Grant: Close

Genomic Fate Maps

Open Date: 2008-02-01

Close Date: 2015-01-31

Grant: Close

NIH Director's Pioneer Award

Open Date: 2007-09-30

Close Date: 2014-07-31

Grant: Close

Mistargeting of Elastase in Bone Marrow Failure

Open Date: 2004-09-30

Close Date: 2010-07-31

Articles (9)

Year:

2026

Year:

2026

Advancements in genetics and genomics continue to further our understanding of their contributions to the development of interstitial lung diseases (ILDs). This state-of-the-art clinical review synthesises current knowledge of the contribution of genetics when evaluating patients suspected to have ILD. We consider highly penetrant Mendelian disorders as well as common variants conferring smaller risk that act in concert with other genetic and acquired risk factors. Additionally, gene-by-environment and pharmacogenomic interactions are discussed to highlight their impact on disease course. Lastly, the approach to genetic ILDs is reviewed from available testing to future directions.

Year:

2025

Pathogenic/likely pathogenic (P/LP) germline variants in RUNX1 cause familial platelet disorder with associated myeloid malignancies (FPDMM), also known as RUNX1- Familial Platelet Disorder (RUNX1-FPD, or FPD), a condition characterized by qualitative and quantitative platelet defects and predisposition to hematopoietic malignancies. Here, we present follow up to a case of a woman with acute myeloid leukemia and lifelong thrombocytopenia which had previously been attributed to presumptive pathogenic (P) GATA2 missense variants. However, re-evaluation with updated molecular technology sensitive for detection of copy number variants (CNVs) led to the identification of a P deletion of exons 5-6 in RUNX1 , which had been undetected when examined at first presentation. This case highlights the importance of comprehensive molecular evaluation and careful variant interpretation, especially regarding CNVs.

Year:

2025

Year:

2025

Objective Mitochondrial DNA (mtDNA) depletion/deletions syndrome (MDDS) comprises a group of diseases caused by primary autosomal defects of mtDNA maintenance. Our objective was to study the etiology of MDDS in 4 patients who lack pathogenic variants in known genetic causes. Methods Whole exome sequencing of the probands was performed to identify pathogenic variants. We validated the mitochondrial defect by analyzing mtDNA, mitochondrial dNTP pools, respiratory chain activities, and GUK1 activity. To confirm pathogenicity of GUK1 deficiency, we expressed 2 GUK1 isoforms in patient cells. Results We identified biallelic GUK1 pathogenic variants in all 4 probands who presented with ptosis, ophthalmoparesis, and myopathic proximal limb weakness, as well as variable hepatopathy and altered T‐lymphocyte profiles. Muscle biopsies from all probands showed mtDNA depletion, deletions, or both, as well as reduced activities of mitochondrial respiratory chain enzymes. GUK1 encodes guanylate kinase, originally identified as a cytosolic enzyme. Long and short isoforms of GUK1 exist. We observed that the long isoform is intramitochondrial and the short is cytosolic. In probands’ fibroblasts, we noted decreased GUK1 activity causing unbalanced mitochondrial dNTP pools and mtDNA depletion in both replicating and quiescent fibroblasts indicating that GUK1 deficiency impairs de novo and salvage nucleotide pathways. Proband fibroblasts treated with deoxyguanosine and/or forodesine, a purine phosphatase inhibitor, ameliorated mtDNA depletion, indicating potential pharmacological therapies. Interpretation Primary GUK1 deficiency is a new and potentially treatable cause of MDDS. The cytosolic isoform of GUK1 may contribute to the T‐lymphocyte abnormality, which has not been observed in other MDDS disorders. ANN NEUROL 2024;96:1209–1224

Year:

2024

Purpose Complex chromosomal rearrangements (CCRs) are rare structural variants involving three or more chromosomal breakpoints. Most de novo reported CCRs pose challenges for diagnosis and management. They often require karyotyping, fluorescence in situ hybridization (FISH), and chromosomal microarray analysis (CMA) for clinical diagnosis because of the limitations of each method. Here we report an inherited exceptionally complex CCR involving 4 chromosomes and 11 breakpoints in a family with multisystem anomalies. Methods We evaluated the CCRs using karyotyping, FISH, CMA, and two emerging genomic technologies: high-throughput chromosome conformation capture sequencing (Hi-C; aka genomic proximity mapping, GPM) and optical genome mapping (OGM). We also performed functional studies using transcriptome and methylome analyses. Results The proband, who had intellectual disability and immune deficiency, shared CCRs with her unaffected mother involving chromosomes 1, 7, and 11 by karyotyping. However, CMA revealed a duplication and three deletions in the proband in contrast to her mother’s balanced genome. Hi-C (GPM) and OGM detected the CCRs and copy number alterations but also uncovered additional breakpoints at high resolution, including an insertion in 4p and two cryptic rearrangements at 7p. Transcriptome and methylome analyses identified likely biological pathways associated with the proband’s phenotypes. Conclusion Combining cytogenetic and genomic methods provided comprehensive characterization and defined the breakpoints at high resolution in both proband and mother. This underscores the value of novel cytogenetic and genomic techniques in deciphering complex genome rearrangements and the significance of integrative genomic analysis and functional characterization in understanding clinical phenotypes.

Year:

2024

Year:

2021

Year:

2020

Collaborators (13)

Shuang Wang

Professor of Biostatistics

Columbia University

UNITED STATES
View details

Glòria Garrabou

University of Barcelona

SPAIN
View details

He Fang

Assisstant Professor

University of Washington

UNITED STATES
View details

Kurenai Tanji

Professor

Columbia University

UNITED STATES
View details

Patrick Hu

Director, Medical Scientist Training Program

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Mahesh Mansukhani

Professor

Columbia University Irving Medical Center

UNITED STATES
View details

David Zhang

Assistant Professor

Columbia University Irving Medical Center

UNITED STATES
View details

Raphael Borie

Praticien Hospitalier

INSERM

FRANCE
View details

Dario Ronchi

Associate Professor

University of Milan

ITALY
View details

Michio Hirano

Assistant/Associate/Full Professor

Columbia University Irving Medical Center

UNITED STATES
View details

Hamish Scott

University of South Australia

AUSTRALIA
View details

Giacomo Comi

Professore Ordinario

Università degli Studi di Torino

ITALY
View details

Antonia Ribes Rubio

Head of the Section of Inborn Errors of Metabolism

Institut d'Investigacions Biomèdiques August Pi i Sunyer

SPAIN
View details